AR048806A1 - Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio - Google Patents

Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio

Info

Publication number
AR048806A1
AR048806A1 ARP040104416A ARP040104416A AR048806A1 AR 048806 A1 AR048806 A1 AR 048806A1 AR P040104416 A ARP040104416 A AR P040104416A AR P040104416 A ARP040104416 A AR P040104416A AR 048806 A1 AR048806 A1 AR 048806A1
Authority
AR
Argentina
Prior art keywords
inflammatory pain
treatment
cariofilenes
affections
medicines
Prior art date
Application number
ARP040104416A
Other languages
English (en)
Inventor
Luiz F Pianowski
Joao B Calixto
Dagoberto De C Brandao
Original Assignee
Ache Lab Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Lab Farmaceuticos Sa filed Critical Ache Lab Farmaceuticos Sa
Publication of AR048806A1 publication Critical patent/AR048806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente se refiere al uso de cariofilenos relacionados con los medicamentos y con el tratamiento de afecciones corporales de inflamacion y dolor inflamatorio. Reivindicaion 9: El uso de cariofilenos o de composiciones que comprenden cariofilenos, segun cualquiera de las reivindicaciones 1 a 4, caracterizado por el hecho de que dichos cariofilenos son uno o más de alfa-humuleno y trans-cariofileno. Reivindicacion 10: Un método para tratar afecciones inflamatorias y dolor inflamatorio del cuerpo animal, particularmente del cuerpo humano, caracterizado por el hecho de que comprende la administracion a un paciente de una cantidad con eficiencia terapéutica de cariofilenos. Reivindicacion 14: Una composicion que comprende cariofileno, caracterizada por el hecho de que la cantidad de dicho cariofileno se encuentra en el orden de 1 a 1000 mg, aproximadamente.
ARP040104416A 2004-10-01 2004-11-29 Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio AR048806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2004/000189 WO2006037194A1 (en) 2004-10-01 2004-10-01 Use of caryophyllenes in the manufacture of medicaments and treatment of bodily conditions of inflammation and inflammatory pain

Publications (1)

Publication Number Publication Date
AR048806A1 true AR048806A1 (es) 2006-05-31

Family

ID=36142256

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104416A AR048806A1 (es) 2004-10-01 2004-11-29 Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio

Country Status (9)

Country Link
US (1) US20080280996A1 (es)
EP (1) EP1809268B1 (es)
JP (1) JP2008514649A (es)
AR (1) AR048806A1 (es)
AT (1) ATE518531T1 (es)
BR (2) BRPI0419105A (es)
CA (1) CA2577219A1 (es)
MX (1) MX2007002116A (es)
WO (1) WO2006037194A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007066305A1 (en) * 2005-12-09 2007-06-14 Zelpy 2549 (Pty) Limited Compositions comprising sesquiterpene compounds for use in the prophylaxis or treatment of pain
US20110028542A1 (en) * 2007-05-31 2011-02-03 Jean Legault Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
JP2012077002A (ja) * 2010-09-30 2012-04-19 Oita Univ ＡＴＬ及びＨＴＬＶ−１関連炎症疾患をターゲットとしたＮＦ−κＢ亢進抑制剤及びその用途
EP2827846B1 (en) * 2012-03-19 2020-08-12 Sharon Anavi-Goffer Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
KR101477552B1 (ko) * 2012-12-07 2014-12-30 세명대학교 산학협력단 유제놀 유도체를 함유하는 아토피성 피부염의 치료용 약제학적 조성물 및 그 제조방법
US20160256410A1 (en) 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10039740B2 (en) * 2015-10-23 2018-08-07 Primus Pharmaceuticals, Inc. Therapeutic combinations of sesquiterpenes and flavonoids
US10456365B2 (en) * 2016-03-25 2019-10-29 Primus Pharmaceuticals, Inc. Methods and formulations for supporting and promoting bone health
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
WO2018033891A1 (en) * 2016-08-19 2018-02-22 Aurea Biolabs Private Limited An anti-inflammatory composition for the treatment of acute joint inflammation and a process for preparation thereof
KR102043893B1 (ko) * 2018-01-05 2019-11-12 인제대학교 산학협력단 알파-휴물렌(alpha-Humulene)을 유효성분으로 포함하는 소화기계 점막 관련 질환 예방 또는 치료용 조성물
KR102040810B1 (ko) * 2018-01-31 2019-11-05 인제대학교 산학협력단 알파-휴물렌을 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987008A (en) 1971-12-17 1976-10-19 Celanese Corporation Flame retardant polyester
NL9100688A (nl) 1991-04-19 1992-11-16 Tno Toepassing van terpenoide verbindingen in de land- of tuinbouw alsmede voor de bereiding van preparaten voor het bestrijden van witte vliegsoorten.
US5314693A (en) 1992-02-07 1994-05-24 Kioritz Corporation Pest control chemicals against pine wood nematodes
JPH07215846A (ja) * 1994-01-28 1995-08-15 Takeda Chem Ind Ltd 抗アレルギー剤
CA2342403A1 (en) 2001-03-28 2002-09-28 Jean Legault Sesquiterpene derivatives as anticancer agents
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
CA2356438A1 (en) * 2001-09-05 2003-03-05 Andre Pichette Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
EP1587482A4 (en) * 2003-01-31 2010-08-25 Technion Res & Dev Foundation ANTI-INFLAMMATORY COMPOSITIONS AND USES THEREOF
JP2005206520A (ja) * 2004-01-22 2005-08-04 Univ Kinki アテローム性動脈硬化抑制剤ならびにこれを含む食品および医薬

Also Published As

Publication number Publication date
CA2577219A1 (en) 2006-04-13
EP1809268A1 (en) 2007-07-25
EP1809268B1 (en) 2011-08-03
BRPI0419105A (pt) 2007-12-11
MX2007002116A (es) 2007-10-16
BRPI0419105B8 (es) 2021-05-25
WO2006037194A1 (en) 2006-04-13
BRPI0419105B1 (pt) 2006-04-13
BR122016029094B1 (pt) 2021-10-13
JP2008514649A (ja) 2008-05-08
US20080280996A1 (en) 2008-11-13
ATE518531T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
ES2254046T1 (es) Tratamiento de hiperplasia prostatica benigna.
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2016054757A1 (es) Composición farmacéutica para prevenir, tratar y curar la rosácea que comprende baba de caracol, manzanilla y propóleo
US20160113986A1 (en) Medicament for treating muscle and skeletal diseases
Wimardhani et al. Oral mucosal ulceration caused by the topical application of a concentrated propolis extract
KR20100137692A (ko) 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
JP2007326839A (ja) 糖尿病、歯周病および関節炎の改善を目的とする健康食品
ES2932359T3 (es) Formulación basada en N-acetilcisteína y urea para el tratamiento de trastornos dermatológicos
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol

Legal Events

Date Code Title Description
FB Suspension of granting procedure